Abstract

Synaptic loss, plaques and neurofibrillary tangles are viewed as hallmarks of Alzheimer’s disease (AD). This study investigated synaptic markers in neocortical Brodmann area 9 (BA9) samples from 171 subjects with and without AD at different levels of cognitive impairment. The expression levels of vesicular glutamate transporters (VGLUT1&2), glutamate uptake site (EAAT2), post-synaptic density protein of 95 kD (PSD95), vesicular GABA/glycine transporter (VIAAT), somatostatin (som), synaptophysin and choline acetyl transferase (ChAT) were evaluated. VGLUT2 and EAAT2 were unaffected by dementia. The VGLUT1, PSD95, VIAAT, som, ChAT and synaptophysin expression levels significantly decreased as dementia progressed. The maximal decrease varied between 12% (synaptophysin) and 42% (som). VGLUT1 was more strongly correlated with dementia than all of the other markers (polyserial correlation = −0.41). Principal component analysis using these markers was unable to differentiate the CDR groups from one another. Therefore, the status of the major synaptic markers in BA9 does not seem to be linked to the cognitive status of AD patients. The findings of this study suggest that the loss of synaptic markers in BA9 is a late event that is only weakly related to AD dementia.

Details

Title
Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer’s disease at various cognitive stages
Author
Poirel, Odile 1 ; Mella, Sébastien 1 ; Videau, Catherine 2 ; Ramet, Lauriane 1 ; Davoli, Maria Antonietta 3 ; Herzog, Etienne 4   VIAFID ORCID Logo  ; Katsel, Pavel 5 ; Naguib Mechawar 3 ; Haroutunian, Vahram 5 ; Epelbaum, Jacques 6 ; Daumas, Stéphanie 1   VIAFID ORCID Logo  ; Salah El Mestikawy 7 

1  Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), Paris, France 
2  Université Sorbonne Paris Cité, UMR-S894 Inserm Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France 
3  Douglas Hospital Research Center, Department of Psychiatry, McGill University, Quebec, QC, Canada 
4  Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), Paris, France; Universités Bordeaux, CNRS, IINS, UMR 5297, Bordeaux, France 
5  Mount Sinai School of Medicine, Department of Psychiatry, NewYork, NY, USA 
6  Université Sorbonne Paris Cité, UMR-S894 Inserm Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France; MECADEV UMR 7179 CNRS, Muséum National d’Histoire Naturelle, Brunoy, France 
7  Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), Paris, France; Douglas Hospital Research Center, Department of Psychiatry, McGill University, Quebec, QC, Canada 
Pages
1-14
Publication year
2018
Publication date
Jan 2018
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41598-018-19154-y
ProQuest document ID
1988493951
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.